573.91
-5.62 (-0.97%)
| Previous Close | 579.53 |
| Open | 582.09 |
| Volume | 576,503 |
| Avg. Volume (3M) | 1,170,093 |
| Market Cap | 60,826,996,736 |
| Price / Earnings (TTM) | 14.46 |
| Price / Earnings (Forward) | 15.92 |
| Price / Sales | 4.59 |
| Price / Book | 2.05 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| TTM Dividend Yield | 0.31% |
| Profit Margin | 31.94% |
| Operating Margin (TTM) | 19.94% |
| Diluted EPS (TTM) | 39.36 |
| Quarterly Revenue Growth (YOY) | -3.70% |
| Quarterly Earnings Growth (YOY) | 12.00% |
| Total Debt/Equity (MRQ) | 9.20% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | 3.95 B |
| Levered Free Cash Flow (TTM) | 2.08 B |
| Return on Assets (TTM) | 6.91% |
| Return on Equity (TTM) | 15.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Regeneron Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Value |
| % Held by Insiders | 1.89% |
| % Held by Institutions | 91.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 850.00 (Canaccord Genuity, 48.11%) | Buy |
| Median | 728.00 (26.85%) | |
| Low | 580.00 (Wells Fargo, 1.06%) | Hold |
| Average | 718.70 (25.23%) | |
| Total | 7 Buy, 3 Hold | |
| Avg. Price @ Call | 547.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 11 Aug 2025 | 812.00 (41.49%) | Buy | 545.94 |
| BMO Capital | 04 Aug 2025 | 640.00 (11.52%) | Buy | 571.54 |
| 02 Jun 2025 | 600.00 (4.55%) | Buy | 490.81 | |
| Guggenheim | 04 Aug 2025 | 815.00 (42.01%) | Buy | 571.54 |
| Morgan Stanley | 04 Aug 2025 | 761.00 (32.60%) | Buy | 571.54 |
| 10 Jul 2025 | 754.00 (31.38%) | Buy | 559.76 | |
| RBC Capital | 04 Aug 2025 | 695.00 (21.10%) | Hold | 571.54 |
| 27 May 2025 | 943.00 (64.31%) | Buy | 603.26 | |
| Canaccord Genuity | 23 Jul 2025 | 850.00 (48.11%) | Buy | 572.39 |
| UBS | 11 Jul 2025 | 584.00 (1.76%) | Hold | 567.74 |
| 05 Jun 2025 | 560.00 (-2.42%) | Hold | 483.07 | |
| JP Morgan | 09 Jun 2025 | 800.00 (39.39%) | Buy | 517.60 |
| Citigroup | 02 Jun 2025 | 650.00 (13.26%) | Buy | 490.81 |
| Wells Fargo | 30 May 2025 | 580.00 (1.06%) | Hold | 490.28 |
| Show more | ||||
No data within this time range.
| TTM Dividend Yield | 0.31% |
| Payout Ratio | 2.24% |
| Expected Next Dividend Payment | Mar 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 18 Aug 2025 | - | 03 Sep 2025 | 0.88 Cash |
| 20 May 2025 | - | 06 Jun 2025 | 0.88 Cash |
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 2.64 | 3 | 0.46 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |